Login
Home
Charts
Search
Watchlist
Products

Vinati Organics Ltd

VINATIORGA·NSE
1,195.00-2.27%Thu, 24 Sept '26 15:57

Vinati Organics Ltd

VINATIORGA
NSE
1,195.00
-2.27%
|Thu, 24 Sept '26 15:57
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
12,378Cr
Close
Close Price
1,194.00
Industry
Industry
Speciality Chemicals
PE
Price To Earnings
27.60
PS
Price To Sales
5.20
Revenue
Revenue
2,381Cr
Rev Gr TTM
Revenue Growth TTM
5.09%
PAT Gr TTM
PAT Growth TTM
5.44%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
463448550525553522648542550531604696
Growth YoY
Revenue Growth YoY%
-18.3-13.36.019.619.516.417.83.3-0.61.7-6.928.4
Expenses
ExpensesCr
358333400400420379468382383374434525
Operating Profit
Operating ProfitCr
105115150124134142180160167157170170
OPM
OPM%
22.625.627.223.724.227.327.829.530.429.528.224.5
Other Income
Other IncomeCr
11910922767169209
Interest Expense
Interest ExpenseCr
111000000000
Depreciation
DepreciationCr
171920212222232626293032
PBT
PBTCr
97103139112134127164141157136160148
Tax
TaxCr
252635282933413742353639
PAT
PATCr
72771048410494123104115101124109
Growth YoY
PAT Growth YoY%
-37.6-28.1-0.521.344.121.818.123.810.17.60.74.5
NPM
NPM%
15.717.218.916.018.918.019.019.220.919.020.515.6
EPS
EPS
7.07.410.18.110.19.011.910.111.19.711.910.5
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
463448550525553522648542550531604696
Growth YoY
Revenue Growth YoY%
-18.3-13.36.019.619.516.417.83.3-0.61.7-6.928.4
Expenses
ExpensesCr
358333400400420379468382383374434525
Operating Profit
Operating ProfitCr
105115150124134142180160167157170170
OPM
OPM%
22.625.627.223.724.227.327.829.530.429.528.224.5
Other Income
Other IncomeCr
11910922767169209
Interest Expense
Interest ExpenseCr
111000000000
Depreciation
DepreciationCr
171920212222232626293032
PBT
PBTCr
97103139112134127164141157136160148
Tax
TaxCr
252635282933413742353639
PAT
PATCr
72771048410494123104115101124109
Growth YoY
PAT Growth YoY%
-37.6-28.1-0.521.344.121.818.123.810.17.60.74.5
NPM
NPM%
15.717.218.916.018.918.019.019.220.919.020.515.6
EPS
EPS
7.07.410.18.110.19.011.910.111.19.711.910.5

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1,0299541,6162,0731,9002,2482,2272,381
Growth
Revenue Growth%
-7.369.328.3-8.318.3-0.95.1
Expenses
ExpensesCr
6156021,1811,5021,4301,6671,5731,716
Operating Profit
Operating ProfitCr
414353434571470581654665
OPM
OPM%
40.236.926.927.624.725.829.427.9
Other Income
Other IncomeCr
4526615239445354
Interest Expense
Interest ExpenseCr
10014100
Depreciation
DepreciationCr
334345597389111118
PBT
PBTCr
425335449563432536595601
Tax
TaxCr
9166103144109131151153
PAT
PATCr
334269347419323405444448
Growth
PAT Growth%
-19.328.720.9-22.925.59.55.4
NPM
NPM%
32.528.221.520.217.018.019.918.8
EPS
EPS
32.526.233.740.431.139.142.843.3
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
1,0299541,6162,0731,9002,2482,2272,381
Growth
Revenue Growth%
-7.369.328.3-8.318.3-0.95.1
Expenses
ExpensesCr
6156021,1811,5021,4301,6671,5731,716
Operating Profit
Operating ProfitCr
414353434571470581654665
OPM
OPM%
40.236.926.927.624.725.829.427.9
Other Income
Other IncomeCr
4526615239445354
Interest Expense
Interest ExpenseCr
10014100
Depreciation
DepreciationCr
334345597389111118
PBT
PBTCr
425335449563432536595601
Tax
TaxCr
9166103144109131151153
PAT
PATCr
334269347419323405444448
Growth
PAT Growth%
-19.328.720.9-22.925.59.55.4
NPM
NPM%
32.528.221.520.217.018.019.918.8
EPS
EPS
32.526.233.740.431.139.142.843.3

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
10101010101010
Reserves
ReservesCr
1,2691,5331,6912,0422,2912,7833,151
Current Liabilities
Current LiabilitiesCr
89108181243218313225
Non Current Liabilities
Non Current LiabilitiesCr
7583107127160175202
Total Liabilities
Total LiabilitiesCr
1,4431,7342,1502,5842,8403,2813,590
Current Assets
Current AssetsCr
6436558261,0669901,0381,217
Non Current Assets
Non Current AssetsCr
8001,0791,3241,5181,8502,2432,373
Total Assets
Total AssetsCr
1,4431,7342,1502,5842,8403,2813,590
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
10101010101010
Reserves
ReservesCr
1,2691,5331,6912,0422,2912,7833,151
Current Liabilities
Current LiabilitiesCr
89108181243218313225
Non Current Liabilities
Non Current LiabilitiesCr
7583107127160175202
Total Liabilities
Total LiabilitiesCr
1,4431,7342,1502,5842,8403,2813,590
Current Assets
Current AssetsCr
6436558261,0669901,0381,217
Non Current Assets
Non Current AssetsCr
8001,0791,3241,5181,8502,2432,373
Total Assets
Total AssetsCr
1,4431,7342,1502,5842,8403,2813,590

Cash Flow

Consolidated
Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
4162191275773458558
Investing Cash Flow
Investing Cash FlowCr
-197-198-255-367-3-443-414
Financing Cash Flow
Financing Cash FlowCr
-109-3-47-86-1-16-141
Net Cash Flow
Net Cash FlowCr
10918-175124-103
Free Cash Flow
Free Cash FlowCr
107170-35517-1-39288
CFO To PAT
CFO To PAT%
124.681.336.6137.81.0113.1125.7
CFO To EBITDA
CFO To EBITDA%
100.562.129.2101.10.778.985.3
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
4162191275773458558
Investing Cash Flow
Investing Cash FlowCr
-197-198-255-367-3-443-414
Financing Cash Flow
Financing Cash FlowCr
-109-3-47-86-1-16-141
Net Cash Flow
Net Cash FlowCr
10918-175124-103
Free Cash Flow
Free Cash FlowCr
107170-35517-1-39288
CFO To PAT
CFO To PAT%
124.681.336.6137.81.0113.1125.7
CFO To EBITDA
CFO To EBITDA%
100.562.129.2101.10.778.985.3

Ratios

Consolidated
Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
7,90814,38920,06418,58715,24916,37713,69112,378
Price To Earnings
Price To Earnings
23.753.457.944.347.240.430.927.6
Price To Sales
Price To Sales
7.715.112.49.08.07.36.25.2
Price To Book
Price To Book
6.29.311.09.16.65.94.33.9
EV To EBITDA
EV To EBITDA
19.040.846.332.632.528.320.918.8
Profitability Ratios
Profitability Ratios
GPM
GPM%
48.347.234.034.734.034.540.140.1
OPM
OPM%
40.236.926.927.624.725.829.427.9
NPM
NPM%
32.528.221.520.217.018.019.918.8
ROCE
ROCE%
33.321.726.027.018.918.818.818.8
ROE
ROE%
26.117.420.420.414.014.514.014.0
ROA
ROA%
23.115.516.116.211.412.312.412.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
7,90814,38920,06418,58715,24916,37713,69112,378
Price To Earnings
Price To Earnings
23.753.457.944.347.240.430.927.6
Price To Sales
Price To Sales
7.715.112.49.08.07.36.25.2
Price To Book
Price To Book
6.29.311.09.16.65.94.33.9
EV To EBITDA
EV To EBITDA
19.040.846.332.632.528.320.918.8
Profitability Ratios
Profitability Ratios
GPM
GPM%
48.347.234.034.734.034.540.140.1
OPM
OPM%
40.236.926.927.624.725.829.427.9
NPM
NPM%
32.528.221.520.217.018.019.918.8
ROCE
ROCE%
33.321.726.027.018.918.818.818.8
ROE
ROE%
26.117.420.420.414.014.514.014.0
ROA
ROA%
23.115.516.116.211.412.312.412.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Vinati Organics is a specialty-chemical manufacturer that turns complex organic chemistry into hard-to-copy industrial ingredients - and it has quietly become the world’s largest producer of two of them. Founded in 1989 by first-generation entrepreneur Vinod Saraf, the company started with a single product and has since built a portfolio of over 30, all anchored in a recurring playbook: develop a cost-efficient, high-purity process that competitors struggle to replicate, then lock in the advantage by making your own raw materials. That backward-integration instinct - owning the molecules upstream so nobody can squeeze you on supply or price - explains almost everything the business has become. # Business segments Two flagship molecules that dominate their global markets, a family of phenol building blocks that feed the rest of the factory, a fast-growing antioxidants business stitched in by acquisition, and a subsidiary nursery for the next generation of niche chemistries - all running on a shared, self-supplied backbone of isobutylene. ## 1. ATBS: the world’s favourite water-treatment monomer **Vinati makes roughly two out of every three tonnes of ATBS sold anywhere on the planet, and the process is so tricky that no one has managed to build a competing plant at scale in India.** - **The molecule that goes everywhere** - ATBS is a monomer (a chemical building block for polymers) used in water treatment, construction, textiles, adhesives, paints, personal care, mining, and oil drilling; personal care, mining and water treatment alone soak up 60-70% of ATBS consumption. - **Sold to giants on long-term deals** - global customers including SNF and Dow buy under multi-year supply contracts, which gives the company volume visibility and makes it harder for a newcomer to poach demand. - **Capacity just got bigger** - a Phase 1 expansion added 10,000 metric tonnes per annum of production capacity, with the new plant starting commercial operations in November 2025, and the company expects ATBS volumes to grow 15-20% in the coming year. - **Tariff-proof** - ATBS is exempt from recent US tariffs, so the dominant export position faces no new trade friction. ## 2. IBB and specialty aromatics: the ibuprofen supply chain starts here **Vinati is also the world’s largest maker of isobutyl benzene, the chemical precursor without which ibuprofen tablets would not exist - and again it holds roughly 65% of the global market.** - **Pharma’s quiet enabler** - IBB’s primary demand driver is consistent ibuprofen production, but it also flows into specialty solvents, paints, agrochemicals, catalysts, electronics and perfumery. - **Same moat, different molecule** - the manufacturing process is complex and hard to replicate, and the company sells to BASF and Mitsubishi under long-term contracts, mirroring the ATBS playbook. - **A temporary raw-material pinch** - IBB volumes dropped about 20% in FY26 because the Iran war disrupted supply of a key input; that bottleneck has been resolved and production is back on track. - **A wider aromatic shelf** - the specialty aromatics basket also includes Normal Butylbenzene, Secondary Butylbenzene, Tertiary Amyl Benzene and several other niche aromatics serving pharma, agrochemical and fragrance end-markets. ## 3. Butyl phenols: the bridge between raw material and finished antioxidant **Vinati is India’s largest butyl-phenols maker and the only domestic producer of four specific types - and because it makes its own isobutylene feedstock, the phenols business is cheaper to run than any rival’s.** - **Two families, two jobs** - mono-butyl phenols (OTBP, PTBP) are sold into fragrances and resins, while di-butyl phenols (2,4-DTBP, 2,6-DTBP) are consumed captively in Veeral Additives to make antioxidants, so the segment is both a revenue stream and an internal supplier. - **New phenols, new markets** - a plant for Ortho Secondary Butyl Phenol and Di-Secondary Butyl Phenol was commissioned at Lote in December 2023, with capacities of 5,000 and 1,000 metric tonnes respectively; Vinati is the only Indian manufacturer of both, and they go into agrochemicals, polystyrene, perfumery and specialty dyes. - **Steady contributor** - the segment delivered stable performance in FY26 and is expected to grow moderately in FY27. ## 4. Antioxidants: the acquisition that doubled the value chain **What began as a separate company - Veeral Additives, India’s largest antioxidants maker - was folded into Vinati in 2024, creating one of the world’s few facilities where the raw material, the intermediate and the finished antioxidant are all made under one roof.** - **Bought, then backward-integrated** - Veeral Additives brought 28,000 tonnes per annum of antioxidant capacity, more than twice India’s domestic demand, and because Vinati already made isobutylene and butyl phenols, the combined entity is doubly backward-integrated: IB → butyl phenols → antioxidants. - **Five products, many plastics** - the basket covers phenolic antioxidants (1010, 1076, 135), a phosphite antioxidant (168) and 10-98, which stop plastics, polypropylene, lube additives and nylon from degrading. - **Growth engine firing** - antioxidants grew revenue 70% in FY25 and another 15% in FY26 despite a tough market, and the company expects strong momentum to continue as it expands into new geographies and develops new grades. ## 5. Customised products (VOPL): the new-chemistry nursery **Vinati’s wholly owned subsidiary Veeral Organics is a dedicated plant for niche molecules that sit outside the main factory’s chemistry - a bet on a dozen new products with about INR 500 crores of capital behind them.** - **A different product slate** - the portfolio includes Anisole, MEHQ (a polymerisation inhibitor), Guaiacol, 4-MAP, isoamylene derivatives and several others, serving flavours, fragrances, personal care, pharma and pesticides. - **Early revenue, more to come** - the customized products segment grew 10% year-on-year in FY26 on rising customer demand; a few products need roughly six months of process re-engineering and should start contributing revenue from the third quarter of FY27. - **R&D as the pipeline** - the in-house R&D team is working on additional molecules, and successful trials will trigger the next round of capital investment, so VOPL functions as both a revenue stream and a laboratory for future engines. # Manufacturing and integration backbone **Four zero-effluent plants, self-generated power and a process-engineering culture that builds factories cheaper per tonne than global benchmarks - this is the operating chassis that every segment runs on.** - **Two sites, one state** - manufacturing is concentrated at Mahad and Lote in Maharashtra, both certified under ISO 9001, ISO 14001, ISO 45001 and the chemical industry’s Responsible Care programme. - **No liquid waste leaves the gate** - the plants operate as zero-effluent-discharge facilities: water is treated, purified through reverse osmosis and multi-effect evaporation, and reused; hazardous waste goes to authorised processors and fly ash is co-processed into bricks for the local community. - **58% of electricity from the sun** - 33 MW of in-house solar capacity across Mahad, Solapur and Osmanabad supplies more than half the company’s power needs. - **The isobutylene advantage** - Vinati is India’s largest maker of isobutylene and high-purity MTBE, achieving 99.85% and 99.97% purity respectively; owning IB production is what makes the ATBS, butyl-phenols and antioxidants chains more cost-efficient than peers who must buy the molecule on the open market. # Group structure and partners **A listed parent with one domestic subsidiary that houses new products, a freshly incorporated US subsidiary, and an acquired antioxidants business now fully absorbed - all debt-free and exporting to more than 40 countries.** - **Veeral Organics (VOPL)** - a 100% domestic subsidiary incorporated in October 2020, built with roughly INR 500 crores of investment, housing the customised-products portfolio. - **Vinati Organics USA** - a wholly owned subsidiary incorporated in Delaware in February 2025, set up to process, distribute, sell and potentially manufacture chemical solutions in the US market. - **The Veeral Additives amalgamation** - effective April 2021 and completed in February 2024, this merger brought 28,000 TPA of antioxidant capacity and double backward integration into the listed entity; VAPL was dissolved and its entire business transferred to Vinati.

Documents — Vinati Organics Ltd

  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/k9rszw47qzakz6z9lrzsdwk4.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/nrtnd5d87zgxcxlaljfojx7e.pdf
  • Q1 FY2025 Earnings Call Transcript (Jun 2024, PDF): https://www.stockscans.in/document/bc5da2yt7q7l33cr5dh72r7h.pdf
  • Q4 FY2024 Earnings Call Transcript (Mar 2024, PDF): https://www.stockscans.in/document/5pqyyqe3ey5sr2ks2q7nd78z.pdf
  • Q3 FY2024 Earnings Call Transcript (Dec 2023, PDF): https://www.stockscans.in/document/goc30xsv0iubtgzi8wgstx6m.pdf
  • Q1 FY2024 Earnings Call Transcript (Jun 2023, PDF): https://www.stockscans.in/document/xu29pu10si2mfcfrdq08vesb.pdf
  • Q3 FY2021 Earnings Call Transcript (Dec 2020, PDF): https://www.stockscans.in/document/3u0cl9z08kcy5a9we2bm0wx7.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/t91j5o515y73f79t5b411a1m.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/sp3i73h4fop9dbr2hqtzg6mz.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/t717fwg6mviqf9yluq6d3exf.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/edlz6u9zawpbaasb5rgpl1od.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/0u5xd0v6kgb3kcn3apim68m9.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/t236hrecjb040f9ri8agf60h.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/yxm8gkov5vyn9ady684o9o0u.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/mofolqv2xuh56rpgniaof30b.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/9tg4mzpdobvx9hhepmid13ia.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/tbh7iswwtlycbt7zichpfght.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/mzio3cshaizxllwfac540a2l.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/f8gho3n5en7x8goougzboibv.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/21ymi4590hnhybi06f8t7stw.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/q4xrvxw7rl19u2w46qlwowzm.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/85dadyl7fsg1xuiw72lq3iwo.pdf

Concall Transcript Summaries — Vinati Organics Ltd

  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AVINATIORGA/transcript-notes/202603/k9rszw47qzakz6z9lrzsdwk4.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AVINATIORGA/transcript-notes/202503/nrtnd5d87zgxcxlaljfojx7e.pdf
  • Q1 FY2025 Concall Transcript Summary (Jun 2024): https://www.stockscans.in/company/NSE%3AVINATIORGA/transcript-notes/202406/bc5da2yt7q7l33cr5dh72r7h.pdf
  • Q4 FY2024 Concall Transcript Summary (Mar 2024): https://www.stockscans.in/company/NSE%3AVINATIORGA/transcript-notes/202403/5pqyyqe3ey5sr2ks2q7nd78z.pdf
  • Q3 FY2024 Concall Transcript Summary (Dec 2023): https://www.stockscans.in/company/NSE%3AVINATIORGA/transcript-notes/202312/goc30xsv0iubtgzi8wgstx6m.pdf
  • Q1 FY2024 Concall Transcript Summary (Jun 2023): https://www.stockscans.in/company/NSE%3AVINATIORGA/transcript-notes/202306/xu29pu10si2mfcfrdq08vesb.pdf